已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer

医学 西妥昔单抗 克拉斯 内科学 临床终点 结直肠癌 肿瘤科 实体瘤疗效评价标准 帕尼单抗 阿维鲁单抗 微卫星不稳定性 临床研究阶段 无进展生存期 彭布罗利珠单抗 化疗 临床试验 癌症 免疫疗法 基因 化学 等位基因 微卫星 生物化学
作者
Erika Martinelli,Giulia Martini,Vincenzo Famiglietti,Teresa Troiani,Stefania Napolitano,Filippo Pietrantonio,Davide Ciardiello,M. Terminiello,C. Borrelli,Pietro Paolo Vitiello,Filippo de Braud,Federica Morano,Antonio Avallone,Nicola Normanno,Anna Nappi,Evaristo Maiello,Tiziana Pia Latiano,Alfredo Falcone,Chiara Cremolini,Daniele Rossini
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:7 (10): 1529-1529 被引量:181
标识
DOI:10.1001/jamaoncol.2021.2915
摘要

IMPORTANCE: Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti-EGFR-based first-line treatment. The association of treatment with cetuximab plus avelumab with overall survival (OS) may be worthy of investigation in this setting. OBJECTIVE: To assess the efficacy and safety of cetuximab rechallenge therapy plus avelumab. DESIGN, SETTING, AND PARTICIPANTS: This single-arm, multicenter phase 2 trial enrolled patients from August 2018 to February 2020. Eligible patients with RAS WT mCRC had a complete or partial response to first-line chemotherapy plus anti-EGFR drugs, developed acquired resistance, and failed second-line therapy. Baseline circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S492R mutation analysis was done. INTERVENTIONS: Patients received avelumab (10 mg/kg every 2 weeks) and cetuximab (400 mg/m2 and, subsequently, 250 mg/m2 weekly) until disease progression or unacceptable toxic effects. MAIN OUTCOMES AND MEASURES: The primary end point was OS. Secondary end points were progression-free survival (PFS), overall response rate (ORR), and safety. RESULTS: Seventy-seven patients were enrolled (42 men, 35 women; median age, 63 years); 71 had microsatellite stable tumors (MSS), 3 microsatellite instability-high tumors (MSI-H), 3 unknown. The study met the primary end point, with median OS (mOS) of 11.6 months (95% CI, 8.4-14.8 months). Median PFS (mPFS) was 3.6 months (95% CI, 3.2-4.1 months). Common grade-3 adverse events were cutaneous eruption, 11 (14%), and diarrhea, 3 (4%). For 67 of 77 (87%) patients, baseline analysis of plasma circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S492R variations was feasible. Forty-eight patients had WT disease, whereas 19 had mutations. Patients with RAS/BRAF WT ctDNA had mOS of 17.3 months (95% CI, 12.5-22.0 months) compared with 10.4 months (95% CI, 7.2-13.6 months) in patients with mutated ctDNA (hazard ratio [HR], 0.49; 95% CI, 0.27-0.90; P = .02). The mPFS was 4.1 months (95% CI, 2.9-5.2 months) in RAS/BRAF WT patients compared with 3.0 months (95% CI, 2.6-3.5 months) in patients with mutated ctDNA (HR, 0.42; 95% CI, 0.23-0.75; P = .004). CONCLUSIONS AND RELEVANCE: The findings of this single-arm phase 2 trial suggest that cetuximab plus avelumab is an active, well tolerated rechallenge therapy in RAS WT mCRC. Plasma ctDNA analysis before treatment may allow selection of patients who could benefit. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04561336.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
笑点低忆之完成签到 ,获得积分10
刚刚
1秒前
顺利的楷瑞完成签到 ,获得积分10
1秒前
1秒前
挚友发布了新的文献求助10
2秒前
布布的应助被健壮的傲之采纳,获得10
2秒前
香锅完成签到,获得积分10
2秒前
认真的莹发布了新的文献求助10
3秒前
健壮绮彤关注了科研通微信公众号
4秒前
5秒前
一丁雨发布了新的文献求助10
6秒前
五嶽完成签到 ,获得积分10
6秒前
8秒前
温暖忆山的应助被雷霆大土豆采纳,获得10
8秒前
Owen的应助被啦啦啦采纳,获得10
8秒前
9秒前
情怀的应助被coco采纳,获得10
9秒前
keke发布了新的文献求助10
12秒前
Preseverance完成签到,获得积分10
13秒前
明亮泽洋完成签到 ,获得积分10
13秒前
14秒前
佳佳发布了新的文献求助10
14秒前
Hello的应助被甜甜的小土豆采纳,获得10
14秒前
LI完成签到,获得积分10
16秒前
luyang发布了新的文献求助20
17秒前
明理的天抒完成签到 ,获得积分10
17秒前
18秒前
Owen的应助被keke采纳,获得10
19秒前
19秒前
十二完成签到 ,获得积分10
21秒前
影月cindy的应助被那个大好人采纳,获得10
21秒前
22秒前
萧衡完成签到 ,获得积分10
22秒前
天灵灵完成签到,获得积分10
23秒前
Mabor完成签到 ,获得积分10
24秒前
Spark完成签到,获得积分10
27秒前
molihuakai的应助被ww_采纳,获得10
28秒前
健壮绮彤发布了新的文献求助10
28秒前
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194689
求助须知:如何正确求助?哪些是违规求助? 9580456
关于积分的说明 21871058
捐赠科研通 7794234
什么是DOI,文献DOI怎么找? 3437711
关于科研通互助平台的介绍 2561001
邀请新用户注册赠送积分活动 2484417